Oric Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary

ORIC Pharmaceuticals

20/03/2023 12:00

* Oric Pharmaceuticals Inc  ORIC.OQ  reported a quarterly
adjusted
loss of 52 cents​​ per share for the quarter ended in December.
The mean expectation of seven analysts for the quarter was for a
loss of 54 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Oric Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 52 cents​.
    * The mean earnings estimate of analysts had risen by
about 3.9%
in the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates 
    * Oric Pharmaceuticals Inc shares had fallen by 22.6% this
quarter.
    * The company reported a quarterly loss of $20.85 million.
    * Wall Street's median 12-month price target for Oric
Pharmaceuticals Inc is $15.00 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 5 "strong buy" or
"buy," 1 "hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
March 20 at 12:00 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.54          -0.52          Beat
 Sep. 30 2022      -0.55          -0.63          Missed
 Jun. 30 2022      -0.60          -0.51          Beat
 Mar. 31 2022      -0.57          -0.59          Missed